摘要
Ifirst met Dr. Andrew V Schally （PhD, MDhc （Multi）, DSc, Distinguished Medical Research Scientist, U.S. Department of Veterans Affairs Professor of Pathology and Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida, USA） many years ago, probably around the beginning of the 1990＇s in one of his visits to Mexico City （Figure 1）. He has many friends in my country since some of the investigations that led to the development of the LHRH agonists were made in a couple of Mexican hospitals in collaboration with some outstanding Mexican physicians that I will mention later. In that time, I was the head of the Department of Urology of the Mexican National Cancer Institute and our Director, Dr. Jaime de la Garza, invited him for a meeting. I was surprised by his humbleness, intelligence and easy going personality, in spite of being a Nobel Prize scientist.
Ifirst met Dr. Andrew V Schally （PhD, MDhc （Multi）, DSc, Distinguished Medical Research Scientist, U.S. Department of Veterans Affairs Professor of Pathology and Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida, USA） many years ago, probably around the beginning of the 1990＇s in one of his visits to Mexico City （Figure 1）. He has many friends in my country since some of the investigations that led to the development of the LHRH agonists were made in a couple of Mexican hospitals in collaboration with some outstanding Mexican physicians that I will mention later. In that time, I was the head of the Department of Urology of the Mexican National Cancer Institute and our Director, Dr. Jaime de la Garza, invited him for a meeting. I was surprised by his humbleness, intelligence and easy going personality, in spite of being a Nobel Prize scientist.
